Ardelyx, Inc. (ARDX) — SEC Filings
Ardelyx, Inc. (ARDX) — 32 SEC filings. Latest: 8-K (Dec 17, 2025). Includes 14 8-K, 6 10-Q, 5 SC 13G/A.
View Ardelyx, Inc. on SEC EDGAR
Overview
Ardelyx, Inc. (ARDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 30, 2025: ARDELYX, INC. reported total revenues of $110.3 million for the three months ended September 30, 2025, an increase from $98.2 million in the same period of 2024. Product sales, net, were the primary driver, growing to $105.5 million from $92.1 million year-over-year. Despite revenue growth, the comp
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 26 neutral, 2 mixed. The dominant filing sentiment for Ardelyx, Inc. is neutral.
Filing Type Overview
Ardelyx, Inc. (ARDX) has filed 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 DEFA14A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ARDX's 22 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $282.1M |
| Net Income | -$61.2M |
| EPS | -$0.25 |
| Debt-to-Equity | 1.30 |
| Cash Position | $42.7M |
| Operating Margin | -16.3% |
| Total Assets | $486.2M |
| Total Debt | $202.1M |
Key Executives
- Trump Administration
- Michael J. Kelly
- Christopher J. Leadem
- Dr. David R. Epstein
- Dr. Steven M. R. Smith
- Laura Hansen
- Mike Markham
- Mike MacIntyre
Industry Context
Ardelyx operates in the biopharmaceutical sector, focusing on novel therapeutics for underserved diseases. The industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Success is heavily dependent on drug efficacy, safety, and successful market access, including favorable reimbursement from payers like Medicare.
Top Tags
10-Q (4) · financials (4) · Revenue Growth (3) · acquisition (3) · merger (3) · private-equity (3) · institutional-ownership (3) · Net Loss (2) · Pharmaceuticals (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total revenues | $110.3M | Increased from $98.2M in Q3 2024 |
| Product sales, net | $105.5M | Increased from $92.1M in Q3 2024 |
| Net loss for Q3 2025 | $0.97M | Widened from $0.81M in Q3 2024 |
| Total revenues for nine months | $282.1M | Increased from $217.5M in 2024 |
| Net loss for nine months | $61.2M | Widened from $43.8M in 2024 |
| Selling, general and administrative expenses for nine months | $250.8M | Increased from $182.6M in 2024 |
| Cash and cash equivalents | $42.7M | Decreased from $64.9M at Dec 31, 2024 |
| Net cash used in operating activities | $63.4M | For the nine months ended Sept 30, 2025 |
| Shares outstanding | 242,974,306 | As of October 23, 2025 |
| Long-term debt | $202.1M | Increased from $150.9M at Dec 31, 2024 |
| Q2 2025 Product Revenue | $45.2M | Increased from $20.1M in Q2 2024, a 125% increase, indicating strong TENERX sales. |
| Q2 2025 Net Loss | $10.5M | Improved from a $25.3M net loss in Q2 2024, showing progress towards profitability. |
| YTD 2025 Total Revenue | $85.3M | Significantly up from $35.1M in YTD 2024, demonstrating sustained growth. |
| Term Loan Principal Balance | $100.0M | As of June 30, 2025, representing a significant financial obligation. |
| Cash and Cash Equivalents | $120.0M | As of June 30, 2025, an increase from $105.0M at December 31, 2024, providing liquidity. |
Frequently Asked Questions
What are the latest SEC filings for Ardelyx, Inc. (ARDX)?
Ardelyx, Inc. has 32 recent SEC filings from Jan 2024 to Dec 2025, including 14 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ARDX filings?
Across 32 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 26 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Ardelyx, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ardelyx, Inc. (ARDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ardelyx, Inc.?
Key financial highlights from Ardelyx, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ARDX?
The investment thesis for ARDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ardelyx, Inc.?
Key executives identified across Ardelyx, Inc.'s filings include Trump Administration, Michael J. Kelly, Christopher J. Leadem, Dr. David R. Epstein, Dr. Steven M. R. Smith and 3 others.
What are the main risk factors for Ardelyx, Inc. stock?
Of ARDX's 22 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Ardelyx, Inc.?
Forward guidance and predictions for Ardelyx, Inc. are extracted from SEC filings as they are enriched.